INSMED INCORPORATED (NASDAQ:INSM) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02 – Results of Operations and Financial Condition.
On May3, 2017,Insmed Incorporated issued a press release
regarding its financial results for the three months ended
March31, 2017. A copy of this press release is furnished herewith
as Exhibit99.1 to this Item 2.02.
The information contained herein, including the Exhibitattached
hereto, shall not be deemed filed for purposes of Section18 of
the Securities Exchange Act of 1934, as amended (the Exchange
Act), or incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such a
filing.
ITEM 9.01 – Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
|
Description |
|
99.1 |
Press Release issued by Insmed Incorporated on May3, 2017. |
About INSMED INCORPORATED (NASDAQ:INSM)
Insmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company’s lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. The Company’s earlier stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil, a vasodilator of pulmonary arterial vascular beds. The Company is conducting a global Phase III clinical study of ARIKAYCE (the 212 or CONVERT study) in adult patients with NTM lung disease caused by Mycobacterium avium complex (MAC), the infective species in NTM lung disease in the United States, Europe and Japan. INSMED INCORPORATED (NASDAQ:INSM) Recent Trading Information
INSMED INCORPORATED (NASDAQ:INSM) closed its last trading session down -0.19 at 18.54 with 382,556 shares trading hands.
